Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes and genomic landscape of patients (pts) with EGFR-mutant lung cancer (EGFR+ LC) with central nervous system (CNS) metastases (mets)
    Meeting Abstract

    Sui, J. S. Y.; Wilcox, J.; Tischfield, S.; Choudhury, N. J.; Riely, G. J.; Kris, M. G.; Boire, A. A.; Yu, H. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    George, S.; Tap, W. D.; von Mehren, M.; Gordon, M. S.; Trent, J. C.; Attia, S.; Zhang, S.; Narasimhan, N.; Rivera, V. M.; Kerstein, D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of naxitamab plus modified dosing of GM-CSF for patients with high-risk neuroblastoma (HR-NB) in first complete remission (CR) or with primary refractory disease
    Meeting Abstract

    Kushner, B. H.; Modak, S.; Basu, E. M.; Iglesias Cardenas, F.; Kramer, K.; Roberts, S. S.; Cheung, N. K. V.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Vij, R.; Escalante, F.; Delforge, M.; Kotowsky, N.; Bitetti, J.; Boytsov, N.; Camadoo-O'Byrne, L.; Powers Happ, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Dreyling, M. H.; Gaidano, G.; González Barca, E.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Tournilhac, O.; Bakuli, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Association of cannabis use with real-world time to treatment discontinuation (rwTTD) in patients with advanced cancer initiating immune checkpoint inhibition (ICI)
    Meeting Abstract

    Zylla, D. M.; Knowlton, G.; Gilmore, G.; Pawloski, P. A.; Salz, T.; Kulkarni, A.; Cowger, J.; Kuranz, S.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)
    Meeting Abstract

    Tolaney, S. M.; Punie, K.; Kurian, A. W.; Ntalla, I.; Verret, W.; Sadetsky, N.; Sjekloca, N.; Stokes, M.; Jhaveri, K. L.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Skin adverse events of anti-cancer treatments: An examination of drug-AE associations
    Meeting Abstract

    Salah, S.; Kerob, D.; Pagès, C.; Lacouture, M. E.; Sibaud, V.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1
    Meeting Abstract

    Tomasson, M. H.; Bahlis, N. J.; Costello, C.; Raje, N. S.; Levy, M. Y.; Dholaria, B. R.; Solh, M. M.; Damore, M. A.; Jiang, S.; Xie, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Patterns, perceptions, and experience with cannabidiol (CBD) after cancer diagnosis
    Meeting Abstract

    Lapen, K.; Mao, J. J.; Raghunathan, N. J.; Jinna, S.; Brens, J.; Hernandez, M.; Korenstein, D.; Salz, T.; Chino, F.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save